Scholarlink

<p><i>MET</i>-amplified glioblastoma (GBM) is rare, accounting for approximately 2–5% of cases. However, the treatment regimens for patients with <i>MET</i>-amplified GBM still have not reached a unanimous consensus. Our paper describes the use of vebreltinib in a newly diagnosed glioblastoma patient harboring <i>MET</i> amplification. This successful case study suggests that novel targeted MET inhibitors may provide potential clinical benefits in select cases on the basis of the MET signaling pathway status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment of a newly diagnosed glioblastoma harboring MET amplification with vebreltinib in combination with radiotherapy: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月17日

查看全文
  • Xinliang Liu,
  • Xin Wang,
  • Pengwei Yan,
  • Dan Zong,
  • Wenjie Guo,
  • Xia He

摘要

MET-amplified glioblastoma (GBM) is rare, accounting for approximately 2–5% of cases. However, the treatment regimens for patients with MET-amplified GBM still have not reached a unanimous consensus. Our paper describes the use of vebreltinib in a newly diagnosed glioblastoma patient harboring MET amplification. This successful case study suggests that novel targeted MET inhibitors may provide potential clinical benefits in select cases on the basis of the MET signaling pathway status.